Cassava Sciences Cleared in Federal Probe, Shifts Focus to Epilepsy Treatment

Biotechnology firm Cassava Sciences has secured a significant legal victory with the U.S. Department of Justice (DOJ) formally closing its investigation into allegations of scientific misconduct. This move concludes years of regulatory uncertainty that had weighed on the company’s legal standing.

Legal Challenges Resolved, Regulatory Hurdles Remain

Investors responded with cautious optimism to the news, pushing the company’s share price up by approximately 2.75%. Market observers view the termination of the federal probe as the removal of a major legal overhang that had clouded the stock for an extended period.

The DOJ’s decision to drop its investigation follows the dismissal of a related lawsuit in October 2025. The agency has now permanently ended its inquiry into claims of manipulated research data for the drug Simufilam. This action marks the conclusion of the major federal investigative proceedings.

This development is the latest in a series of legal resolutions for the company. In September 2024, Cassava Sciences reached a settlement with the U.S. Securities and Exchange Commission (SEC). As part of that agreement, the firm paid a financial penalty to resolve accusations of negligent disclosure violations without formally admitting to the charges.

Should investors sell immediately? Or is it worth buying Cassava Sciences?

Pipeline Reorientation Underway

With these legal disputes now settled, company leadership is pivoting its focus to restructuring its clinical development pipeline. The original Alzheimer’s disease program was terminated after Phase 3 trials failed to meet their primary endpoints in late 2024 and early 2025.

The company’s current emphasis is on developing therapies for epilepsy associated with Tuberous Sclerosis Complex (TSC). However, this new direction faces immediate regulatory obstacles. Since January 2026, the U.S. Food and Drug Administration (FDA) has imposed a clinical hold on the planned TSC study. The regulator is requesting additional preclinical data and protocol modifications before clinical testing can resume.

The management team’s immediate challenge is to address the FDA’s technical requirements to advance its remaining clinical candidates. The closure of the DOJ investigation removes a key distraction, allowing the company to concentrate its resources on navigating these regulatory barriers.